Table 2

Enhancement of efficacy of TMZ in human pancreatic xenografts in athymic mice with the MGMT inhibitors BG and dBG

Mice no.Treatment (dose)aWeight lossRegressionb %cT to 5× (days)dT-C (days)e
PANC-1 (MGMT = 680 fmol/mg protein)
10None0.011 (8–14)
10TMZ (340)f8.63/1024 (18–33)13
10TMZ (170), BG (160)8.53/1026 (21–27)15
10TMZ (170), dBG (260)5.34/1028 (24–36)17
MIA PaCa-2 (MGMT = 890 fmol/mg protein)
10None0.014 (11–25)
10TMZ (340)10.94/1018 (16–27)4
10TMZ (170), BG (160)9.04/1023 (20–33)9
10TMZ (170), dBG (260)11.64/1023 (20–31)9
CAPAN-2 (MGMT = 620 fmol/mg protein)
10None0.022 (16–26)
10TMZ (340)12.39/1054 (42–66)32
10TMZ (170), BG (160)9.99/1066 (32–88)44
10TMZ (170), dBG (260)10.610/1078 (66–94)56
CFPAC-1 (MGMT = 1680 fmol/mg protein)
10None0.019 (18–22)
10TMZ (340)11.94/1021 (19–28)3
14TMZ (170), BG (160)9.97/1432 (25–33)13
10TMZ (170), dBG (260)10.65/1036 (24–45)17
  • a mg/m2.

  • b Reduction of tumor volume by ≥10%.

  • c Average weight loss after treatment.

  • d Time for tumor to quintuple from its treatment size of 180–200 mm3.

  • e Tumor delay.

  • f TMZ was administered 2 h after BG and 4 h after dBG.